-
2023.05.26
J-Pharma announces Publication of the Abstract on the Japan Phase 2 study of nanvuranlat (development code: JPH203) for advanced refractory biliary tract cancer patients at the American Society of Clinical Oncology (ASCO) Annual Meeting. Nanvuranlat is an L-type amino acid transporter 1 (LAT1) inhibitor
-
What's new
- J-Pharma Presented the latest findings on LAT1 inhibitor NANVURANLAT (development code: JPH203) at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI2024) 2024/01/22
- J-Pharma Presenting at the J.P. Morgan Healthcare Conference 2024 for the Fourth Consecutive Year 2024/01/12
- Announcement of presentation at the J.P. Morgan Healthcare Conference 2024 2023/12/13
- Financing total 2.4 billion yen completed through a third-party allotment of new shares (Round E) 2023/10/05
- J-Pharma Receives Award from the National Multiple Sclerosis Society to Develop JPH034 as a Potential Treatment for Progressive Multiple Sclerosis 2023/10/05
-
Monthly
- 2024.01 (2)
- 2023.12 (1)
- 2023.10 (3)
- 2023.06 (3)
- 2023.05 (1)
- 2023.04 (1)
- 2023.03 (2)
- 2023.01 (3)
- 2022.12 (2)
- 2022.05 (1)
- 2022.04 (1)
- 2022.01 (1)
- 2021.11 (1)
- 2021.07 (1)
- 2021.03 (2)
- 2021.02 (1)
- 2021.01 (2)
- 2020.07 (1)
- 2020.06 (1)
- 2019.12 (1)
- 2019.04 (1)
- 2018.12 (1)
- 2018.07 (1)
- 2018.05 (1)
- 2018.03 (1)
- 2018.01 (1)
- 2017.09 (1)
- 2016.05 (1)
- 2015.11 (1)
- 2015.04 (1)
- 2015.02 (1)